Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

Stock Information for Reviva Pharmaceuticals Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Reviva Pharmaceuticals Holdings Inc.

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Reviva to Participate in the 2025 BIO CEO & Investor Conference
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
Reviva Announces Proposed Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.